Clin Infect Dis. 2018 Mar 5;66(6):893-903. doi: 10.1093/cid/cix915.
Early initiation of combination antiretroviral therapy (cART), at higher CD4 cell counts, prevents disease progression and reduces sexual transmission of human immunodeficiency virus (HIV). We describe the temporal trends in CD4 cell counts at the start of cART in adults from low-income, lower-middle-income, upper-middle-income, and high-income countries (LICs, LMICs, UMICs, and HICs, respectively).
We included HIV-infected individuals aged ≥16 years who started cART between 2002 and 2015 in a clinic participating in the International epidemiology Databases to Evaluate AIDS (IeDEA) or the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). Missing CD4 cell counts at the start of cART were estimated through multiple imputation. Weighted mixed-effect models were used to smooth trends in median CD4 cell counts.
A total of 951855 adults from 16 LICs, 11 LMICs, 9 UMICs, and 19 HICs were included. Overall, the modeled median CD4 cell count at the start of cART increased from 2002 to 2015, from 78/µL (95% confidence interval, 58-104/µL) to 287/µL (250-328/µL) in LICs, from 99/µL (71-140/µL) to 234/µL (192-285/µL) in LMICs, from 71/µL (49-104/µL) to 311/µL (255-379/µL) in UMICs, and from 161/µL (143-181/µL) to 327/µL (286-372/µL) in HICs. In LICs, LMICs, and UMICs, the increase was more pronounced in women; in HICs, the opposite was observed.
Median CD4 cell counts at the start of cART increased in all income groups, but generally remained below 350/μL in 2015. Substantial additional efforts and resources are required to achieve earlier diagnosis, linkage to care, and initiation of cART.
早期开始联合抗逆转录病毒疗法(cART),在较高的 CD4 细胞计数时,可以预防疾病进展并降低人类免疫缺陷病毒(HIV)的性传播。我们描述了来自低收入、中低收入、中高收入和高收入国家(LICs、LMICs、UMICs 和 HICs)的成年人开始 cART 时的 CD4 细胞计数的时间趋势。
我们纳入了 2002 年至 2015 年期间在参与国际艾滋病流行病学数据库评估(IeDEA)或欧洲观察性艾滋病毒流行病学合作(COHERE)的诊所开始 cART 的年龄≥16 岁的 HIV 感染者。通过多次插补估计 cART 开始时 CD4 细胞计数的缺失值。使用加权混合效应模型来平滑中位数 CD4 细胞计数的趋势。
共纳入了来自 16 个 LICs、11 个 LMICs、9 个 UMICs 和 19 个 HICs 的 951855 名成年人。总体而言,cART 开始时的模型化中位数 CD4 细胞计数从 2002 年到 2015 年增加,从 LICs 的 78/µL(95%置信区间 58-104/µL)增加到 287/µL(250-328/µL),从 LMICs 的 99/µL(71-140/µL)增加到 234/µL(192-285/µL),从 UMICs 的 71/µL(49-104/µL)增加到 311/µL(255-379/µL),从 HICs 的 161/µL(143-181/µL)增加到 327/µL(286-372/µL)。在 LICs、LMICs 和 UMICs 中,女性的增长更为明显;而在 HICs 中,情况则相反。
cART 开始时的 CD4 细胞计数中位数在所有收入群体中均有所增加,但 2015 年仍普遍低于 350/µL。需要进一步投入大量资源,以实现更早的诊断、与护理的联系以及 cART 的启动。